Seeking Alpha

While Pharmasset (VRUS) shareholders stand to reap a windfall from Gilead Sciences’ (GILD)...

While Pharmasset (VRUS) shareholders stand to reap a windfall from Gilead Sciences’ (GILD) $11B takeover offer, its top execs are also in line for fat paydays. According to SEC filings reviewed by Footnoted, VRUS CEO P. Schaefer Price could pocket $255M once the deal closes, and other top brass also would grow much richer.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs